Open Label Extension Study of AMG 531 in Japanese Subjects With ITP
This study has been completed.
Kyowa Hakko Kirin Company, Limited
Information provided by (Responsible Party):
Kyowa Hakko Kirin Co., Ltd ( Kyowa Hakko Kirin Company, Limited )
First received: February 22, 2007
Last updated: September 11, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||September 2011|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377.